www.highlighttherapeutics.com Open in urlscan Pro
198.49.23.145  Public Scan

Form analysis
0 forms found in the DOM

Text Content

0
Skip to Content


Current Page: Home
About
About us
Management
Advisory Board
Science
Science
Pipeline
Investors
Contact
News

Open Menu Close Menu

Current Page: Home
About
About us
Management
Advisory Board
Science
Science
Pipeline
Investors
Contact
News

Open Menu Close Menu

Current Page: Home
Folder: About
Folder: Science
Investors
Contact
News

Back
About us
Management
Advisory Board
Back
Science
Pipeline
 


UNLOCKING THE POTENTIAL OF IMMUNO-ONCOLOGY

HIGHLIGHT THERAPEUTICS IS A PRIVATE, CLINICAL-STAGE COMPANY DEDICATED TO
UNLOCKING THE FULL POTENTIAL OF IMMUNO-ONCOLOGY.

ABOUT HIGHLIGHT THERAPEUTICS

 
 
 

Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has
been demonstrated to initiate a powerful immune response, leveraging a unique
multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the
immune system.

 
Pipeline

 
 


UNLOCKING THE POTENTIAL OF IO

Watch our video and discover how BO-112 is unlocking the potential of IO.


NEWS

Highlight Therapeutics & Cima announce positive results from pre-clinical study
combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer



2nd December 2021

Download PDF

Highlight announces positive preliminary results from Phase 2b study of
BO-112+anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC

12th November 2021

Download PDF
 

Highlight Therapeutics, S.L.
Parque Científico Universidad de Valencia
Calle Catedrático Agustín Escardino, 9
Paterna 46980 (Valencia)
Spain


About Us


Pipeline
News
Investors
Contact

Website designed by:
Hawk & Handsaw